Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.

Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY.

Nature. 2002 Jun 27;417(6892):975-8. Epub 2002 Jun 5.

PMID:
12050673
2.

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.

Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP.

Science. 2002 Jun 7;296(5574):1886-9. Epub 2002 May 9.

3.
5.

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.

Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.

6.

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.

IUBMB Life. 2001 Jul;52(1-2):43-7. Review.

7.

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.

8.
9.

Quantifying the Binding Interaction between the Hypoxia-Inducible Transcription Factor and the von Hippel-Lindau Suppressor.

Domene C, Jorgensen C, Vanommeslaeghe K, Schofield CJ, MacKerell A Jr.

J Chem Theory Comput. 2015 Aug 11;11(8):3946-54. doi: 10.1021/acs.jctc.5b00411.

10.

Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau.

Lee C, Kim SJ, Jeong DG, Lee SM, Ryu SE.

J Biol Chem. 2003 Feb 28;278(9):7558-63. Epub 2002 Dec 12.

11.

Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.

Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ.

EMBO J. 2001 Sep 17;20(18):5197-206.

12.
13.

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Maynard MA, Ohh M.

Am J Nephrol. 2004 Jan-Feb;24(1):1-13. Epub 2003 Dec 3. Review.

15.

Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.

Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.

J Biol Chem. 2003 Mar 28;278(13):11032-40. Epub 2003 Jan 21.

17.

The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G.

EMBO J. 2003 Apr 15;22(8):1857-67.

18.

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.

Nature. 1999 May 20;399(6733):271-5.

PMID:
10353251
19.

The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.

Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.

Oncogene. 2001 Aug 16;20(36):5067-74.

20.

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.

Tanimoto K, Makino Y, Pereira T, Poellinger L.

EMBO J. 2000 Aug 15;19(16):4298-309.

Supplemental Content

Support Center